Medcura, Inc. is a commercial-stage medical device company developing versatile hemostatic products serving surgical, medical, and consumer market opportunities.
The company’s proprietary technology platform combines safe, inert ingredients with patented chemistries, all aimed at introducing lower-cost products capable of safely and effectively controlling bleeding across a broad spectrum of clinical applications.
Medcura has received FDA Breakthrough Device Designations for LifeGel™, which controls surgical bleeding for spine surgeries, and LifeFoam™, a hemostatic agent for traumatic wounds.
Medcura’s products use a proprietary modification of chitosan, a nontoxic, biodegradable biopolymer found in the shells of crustaceans and certain plants, to stop bleeding while preventing harmful bacteria from growing. It’s an invention of company co-founder Matthew Dowling Ph.D. ’10, who started researching the material as a bioengineering student in the A. James Clark School of Engineering in the lab of Department of Chemical and Biomolecular Engineering Professor Srinivasa Raghavan.
Dowling is now Medcura’s chief scientific officer and director.
Medcura has acquired five FDA clearances, two FDA Breakthrough Device Designations, 28 issued patents, and more than ten peer-reviewed articles in high-impact scientific journals.
Funding: $49.75 million
Employees: 31
Programs: Mtech Ventures, MIPS, Dingman Center for Entrepreneurship, Discovery District
